Indeed, stool samples from CRC patients frequently revealed methylated GATA4 promoter DNA, but the sensitivity of the assay requires further improvement to be useful clinically.[29] In conceptually related studies, GATA 4 and GATA5 were found to be extinguished in a large fraction of lung and esophageal cancers.[31] GATA4 and GATA5 promoter methylation and loss of expression were detected in 67% and 41% respectively, in primary human lung cancers, while GATA6 was continuously expressed.[32]. This evidence concerns the gene GATA4 and esophageal cancer.